Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 87


Production of α-galactosylceramide by a prominent member of the human gut microbiota.

Wieland Brown LC, Penaranda C, Kashyap PC, Williams BB, Clardy J, Kronenberg M, Sonnenburg JL, Comstock LE, Bluestone JA, Fischbach MA.

PLoS Biol. 2013 Jul;11(7):e1001610. doi: 10.1371/journal.pbio.1001610. Epub 2013 Jul 16.


Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.

Hogan AE, O'Reilly V, Dunne MR, Dere RT, Zeng SG, O'Brien C, Amu S, Fallon PG, Exley MA, O'Farrelly C, Zhu X, Doherty DG.

Clin Immunol. 2011 Aug;140(2):196-207. doi: 10.1016/j.clim.2011.03.016. Epub 2011 Apr 13.


Production and characterization of monoclonal antibodies against complexes of the NKT cell ligand alpha-galactosylceramide bound to mouse CD1d.

Yu KO, Im JS, Illarionov PA, Ndonye RM, Howell AR, Besra GS, Porcelli SA.

J Immunol Methods. 2007 May 31;323(1):11-23. Epub 2007 Apr 5.


Production of both IL-27 and IFN-gamma after the treatment with a ligand for invariant NK T cells is responsible for the suppression of Th2 response and allergic inflammation in a mouse experimental asthma model.

Fujita H, Teng A, Nozawa R, Takamoto-Matsui Y, Katagiri-Matsumura H, Ikezawa Z, Ishii Y.

J Immunol. 2009 Jul 1;183(1):254-60. doi: 10.4049/jimmunol.0800520.


The molecular basis for recognition of CD1d/α-galactosylceramide by a human non-Vα24 T cell receptor.

López-Sagaseta J, Kung JE, Savage PB, Gumperz J, Adams EJ.

PLoS Biol. 2012;10(10):e1001412. doi: 10.1371/journal.pbio.1001412. Epub 2012 Oct 23.


Amide analogues of CD1d agonists modulate iNKT-cell-mediated cytokine production.

Wojno J, Jukes JP, Ghadbane H, Shepherd D, Besra GS, Cerundolo V, Cox LR.

ACS Chem Biol. 2012 May 18;7(5):847-55. doi: 10.1021/cb2005017. Epub 2012 Feb 29.


Dissociated expression of natural killer 1.1 and T-cell receptor by invariant natural killer T cells after interleukin-12 receptor and T-cell receptor signalling.

Emoto M, Shimizu T, Koike H, Yoshizawa I, Hurwitz R, Kaufmann SH, Emoto Y.

Immunology. 2010 Jan;129(1):62-74. doi: 10.1111/j.1365-2567.2009.03148.x.


Invariant natural killer T cell-natural killer cell interactions dictate transplantation outcome after alpha-galactosylceramide administration.

Kuns RD, Morris ES, Macdonald KP, Markey KA, Morris HM, Raffelt NC, Banovic T, Don AL, Rowe V, Burman AC, Clouston AD, Farah C, Besra GS, Illarionov PA, Smyth MJ, Porcelli SA, Hill GR.

Blood. 2009 Jun 4;113(23):5999-6010. doi: 10.1182/blood-2008-10-183335. Epub 2009 Apr 15.


Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.

Wu L, Gabriel CL, Parekh VV, Van Kaer L.

Tissue Antigens. 2009 Jun;73(6):535-45. doi: 10.1111/j.1399-0039.2009.01256.x. Epub 2009 Apr 8. Review.


Galactose-modified iNKT cell agonists stabilized by an induced fit of CD1d prevent tumour metastasis.

Aspeslagh S, Li Y, Yu ED, Pauwels N, Trappeniers M, Girardi E, Decruy T, Van Beneden K, Venken K, Drennan M, Leybaert L, Wang J, Franck RW, Van Calenbergh S, Zajonc DM, Elewaut D.

EMBO J. 2011 Jun 1;30(11):2294-305. doi: 10.1038/emboj.2011.145. Epub 2011 May 6.


Role of invariant natural killer T (iNKT) cells in systemic lupus erythematosus.

Godó M, Sessler T, Hamar P.

Curr Med Chem. 2008;15(18):1778-87. Review.


The complementarity determining region 2 of BV8S2 (V beta 8.2) contributes to antigen recognition by rat invariant NKT cell TCR.

Pyz E, Naidenko O, Miyake S, Yamamura T, Berberich I, Cardell S, Kronenberg M, Herrmann T.

J Immunol. 2006 Jun 15;176(12):7447-55.


Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases.

Gadola SD, Silk JD, Jeans A, Illarionov PA, Salio M, Besra GS, Dwek R, Butters TD, Platt FM, Cerundolo V.

J Exp Med. 2006 Oct 2;203(10):2293-303. Epub 2006 Sep 18.


Activation or anergy: NKT cells are stunned by alpha-galactosylceramide.

Sullivan BA, Kronenberg M.

J Clin Invest. 2005 Sep;115(9):2328-9.


Interleukin-2 gene transfer potentiates the alpha-galactosylceramide-stimulated antitumor effect by the induction of TRAIL in NKT and NK cells in mouse models of subcutaneous and metastatic carcinoma.

Nishihori Y, Kato K, Tanaka M, Okamoto T, Hagiwara S, Araki N, Kogawa K, Kuribayashi K, Nakamura K, Niitsu Y.

Cancer Biol Ther. 2009 Sep;8(18):1763-70.


Syntheses of biotinylated alpha-galactosylceramides and their effects on the immune system and CD1 molecules.

Sakai T, Naidenko OV, Iijima H, Kronenberg M, Koezuka Y.

J Med Chem. 1999 May 20;42(10):1836-41.


A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen.

Hameg A, Apostolou I, Leite-De-Moraes M, Gombert JM, Garcia C, Koezuka Y, Bach JF, Herbelin A.

J Immunol. 2000 Nov 1;165(9):4917-26.


The development of airway hyperreactivity in T-bet-deficient mice requires CD1d-restricted NKT cells.

Kim HY, Pichavant M, Matangkasombut P, Koh YI, Savage PB, DeKruyff RH, Umetsu DT.

J Immunol. 2009 Mar 1;182(5):3252-61. doi: 10.4049/jimmunol.0803339.


α-Galactosylceramide-induced airway eosinophilia is mediated through the activation of NKT cells.

Chuang YH, Wang TC, Jen HY, Yu AL, Chiang BL.

J Immunol. 2011 Apr 15;186(8):4687-92. doi: 10.4049/jimmunol.1003659. Epub 2011 Mar 7.


CLN3p impacts galactosylceramide transport, raft morphology, and lipid content.

Rusyn E, Mousallem T, Persaud-Sawin DA, Miller S, Boustany RM.

Pediatr Res. 2008 Jun;63(6):625-31. doi: 10.1203/PDR.0b013e31816fdc17.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk